Table 3.
Univariate and Multivariate Analyses of the Prognostic Factors for OS in NSCLC Patients with Brain Metastases
| Factors | Univariate Analysis | Multivariate Analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| mOS, mo | 2-Year OS, % | χ2 | P | HR | 95% CI | χ2 | P | |
| Age, years | ||||||||
| ≥65 | 20.5 | 0.0 | 0.60 | 0.438 | 1.319 | 0.431–4.039 | 0.235 | 0.628 |
| <65 | 21.3 | 42.2 | ||||||
| Sex | ||||||||
| Male | 21.2 | 32.5 | 1.51 | 0.220 | 1.643 | 0.624–4.321 | 1.011 | 0.315 |
| Female | 22.3 | 44.2 | ||||||
| KPS score | ||||||||
| ≥80 | 21.2 | 39.4 | 0.02 | 0.897 | 0.771 | 0.254–2.337 | 0.211 | 0.646 |
| <80 | 22.3 | 35.0 | ||||||
| Smoking status | ||||||||
| Never | 20.5 | 39.0 | 0.19 | 0.666 | 1.192 | 0.427–3.327 | 0.112 | 0.738 |
| Ever | 21.2 | 37.0 | ||||||
| Brain metastasis | ||||||||
| Symptomatic | 27.5 | 54.9 | 3.65 | 0.056 | 0.479 | 0.218–1.053 | 3.358 | 0.067 |
| Asymptomatic | 17.6 | 26.5 | ||||||
| EGFR mutation status assessment* | ||||||||
| Positive | 23.1 | 44.0 | 0.59 | 0.443 | ||||
| Wild type | 20.5 | 45.3 | ||||||
| No. of first-line chemotherapy cycles | ||||||||
| ≥6 | 21.5 | 40.4 | 0.68 | 0.409 | 0.615 | 0.228–1.315 | 1.571 | 0.210 |
| <6 | 20.5 | 37.2 | ||||||
| Maintenance | ||||||||
| Yes | 22.3 | 41.4 | 0.39 | 0.531 | 0.939 | 0.449–1.963 | 0.028 | 0.867 |
| No | 17.6 | 34.5 | ||||||
| Thoracic radiation | ||||||||
| Yes | 20.5 | 49.0 | 0.30 | 0.585 | 0.869 | 0.351–2.151 | 0.092 | 0.762 |
| No | 21.2 | 33.4 | ||||||
| Brain radiation | ||||||||
| Yes | 21.3 | 40.4 | 0.94 | 0.332 | 0.856 | 0.347–2.115 | 0.113 | 0.737 |
| No | 21.2 | 36.8 | ||||||
| Bevacizumab | ||||||||
| Yes | 21.0 | 45.9 | 0.55 | 0.460 | 1.173 | 0.528–2.608 | 0.154 | 0.695 |
| No | 21.0 | 39.5 | ||||||
Note: *Indicates that the patients’ EGFR mutation status was assessable.
Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance status; EGFR, epidermal growth factor receptor.